January 9, 2017 / 12:44 PM / 7 months ago

BRIEF-Enanta reports high SVR12 rates achieved in Genotype 1 chronic HCV infected Japanese patients

Jan 9 (Reuters) - Enanta Pharmaceuticals Inc

* Enanta - in certain-1 study, 99 percent genotype 1 chronic hepatitis-C infected Japanese patients without cirrhosis got svr 12 with 8 weeks of G/P treatment

* One patient who did not reach SVR12IN this intent to treat population was lost to follow-up

* Primary endpoint of study was met, as 8 weeks of G/P was shown to be non-inferior to 12 weeks of OBV/PTV/R Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below